Updated: Nov 8, 2023
Dr. Robert Rissman's paper "Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease" has now been published.
The paper looks at incorporating blood-based Alzheimer's disease biomarkers into screening algorithms to improve efficiency. Including plasma p-tau217/np-tau217 and Aβ42/Aβ40 in predictive algorithms may streamline screening preclinical individuals into anti-amyloid clinical trials.
Co-authors of the paper include ATRI's Oliver Langford, Dr. Rema Raman, Dr. Mike Donohue, Gustavo Jimenez-Maggiora, Dr. Michael Rafii, and Dr. Paul Aisen.
Original Post: October 26, 2023
The Clinical Trials on Alzheimer's Disease (CTAD) conference kicked off in Boston this week and ATRI's Robert Rissman will be giving a presentation to provide insight into some of the work being done by ACTC members such as himself. Dr. Rissman is Professor of Physiology and Neuroscience and the W.M. Keck Endowed Professor in Medicine and is the founding Director of the Neuroscience Translational Research Division and the ATRI Biomarker Laboratory and Biorepository. He is also the ACTC Biorepository Unit Lead.
Oct 26th, 5:05pm - Implementing blood biomarkers in clinical practice and trials.
Presentation 3: Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s Disease.
You can also view the entire CTAD conference schedule.
